KR100995390B1 - 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 - Google Patents
무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 Download PDFInfo
- Publication number
- KR100995390B1 KR100995390B1 KR1020060000276A KR20060000276A KR100995390B1 KR 100995390 B1 KR100995390 B1 KR 100995390B1 KR 1020060000276 A KR1020060000276 A KR 1020060000276A KR 20060000276 A KR20060000276 A KR 20060000276A KR 100995390 B1 KR100995390 B1 KR 100995390B1
- Authority
- KR
- South Korea
- Prior art keywords
- docetaxel
- solvent
- crystalline
- hydrated
- purity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 title claims abstract description 177
- 229960003668 docetaxel Drugs 0.000 title claims abstract description 177
- 238000000034 method Methods 0.000 title claims abstract description 48
- 238000002360 preparation method Methods 0.000 title claims description 3
- 238000001914 filtration Methods 0.000 claims abstract description 6
- 239000002244 precipitate Substances 0.000 claims description 35
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 24
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 12
- 239000012454 non-polar solvent Substances 0.000 claims description 12
- 238000001035 drying Methods 0.000 claims description 9
- OFBQJSOFQDEBGM-UHFFFAOYSA-N Pentane Chemical compound CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 claims description 8
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 8
- 239000002798 polar solvent Substances 0.000 claims description 6
- 239000002904 solvent Substances 0.000 abstract description 32
- 239000013078 crystal Substances 0.000 abstract description 22
- 238000001556 precipitation Methods 0.000 abstract description 14
- 239000000084 colloidal system Substances 0.000 abstract description 8
- 238000001291 vacuum drying Methods 0.000 abstract description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 48
- 239000008213 purified water Substances 0.000 description 40
- 238000004519 manufacturing process Methods 0.000 description 31
- 239000003960 organic solvent Substances 0.000 description 31
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 24
- 239000000243 solution Substances 0.000 description 22
- 239000012046 mixed solvent Substances 0.000 description 20
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 18
- 239000007853 buffer solution Substances 0.000 description 12
- 239000002245 particle Substances 0.000 description 12
- 238000002425 crystallisation Methods 0.000 description 11
- 238000004458 analytical method Methods 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 9
- 239000000126 substance Substances 0.000 description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 8
- 230000008025 crystallization Effects 0.000 description 8
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- 125000004432 carbon atom Chemical group C* 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 5
- 230000000052 comparative effect Effects 0.000 description 5
- 230000036571 hydration Effects 0.000 description 5
- 238000006703 hydration reaction Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
- 150000001298 alcohols Chemical class 0.000 description 4
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 238000001953 recrystallisation Methods 0.000 description 4
- 150000004684 trihydrates Chemical class 0.000 description 4
- ZDZOTLJHXYCWBA-MQOKZWAMSA-N 7-epidocetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-MQOKZWAMSA-N 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 150000004683 dihydrates Chemical class 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 150000002576 ketones Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 150000004682 monohydrates Chemical class 0.000 description 3
- 239000013557 residual solvent Substances 0.000 description 3
- 238000004626 scanning electron microscopy Methods 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- YWLXLRUDGLRYDR-ZHPRIASZSA-N 5beta,20-epoxy-1,7beta,10beta,13alpha-tetrahydroxy-9-oxotax-11-ene-2alpha,4alpha-diyl 4-acetate 2-benzoate Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](O)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 YWLXLRUDGLRYDR-ZHPRIASZSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 2
- 229940123237 Taxane Drugs 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 229910021529 ammonia Inorganic materials 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001924 cycloalkanes Chemical class 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 239000012535 impurity Substances 0.000 description 2
- -1 paclitaxel Chemical compound 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001376 precipitating effect Effects 0.000 description 2
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000010792 warming Methods 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- 241001116498 Taxus baccata Species 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000007857 degradation product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000006866 deterioration Effects 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- XCDIRYDKECHIPE-QHEQPUDQSA-N docetaxel trihydrate Chemical compound O.O.O.O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 XCDIRYDKECHIPE-QHEQPUDQSA-N 0.000 description 1
- 229950010692 docetaxel trihydrate Drugs 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- ZYBWTEQKHIADDQ-UHFFFAOYSA-N ethanol;methanol Chemical compound OC.CCO ZYBWTEQKHIADDQ-UHFFFAOYSA-N 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000000935 solvent evaporation Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000007738 vacuum evaporation Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epoxy Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Description
측정기기 | Rigaku, D/MAX 3B, XRPD |
측정방법 | 시료 약 20 mg 을 XRPD sampler에 정착, 상온에서 분으로 5℃에서 25℃까지 스캐닝하여 측정. |
X-선 소스 | CuKα 40kV, 40mA |
기기 | Hewlett Packard 1100 HPLC |
컬럼 | Curosil PFP 4.6X50, 5micron |
컬럼 온도 | 35℃ |
이동상 | 아세토나이트릴:물(35-65% 농도구배) |
유속 | 1ml/min |
주입량 | 10ul |
검출기 | UV(227nm) |
MeOH | EtOH | |||
도세탁셀 순도 변화(%) | 7-epi-docetaxel 생성량 (area%) | 도세탁셀 순도 변화(%) | 7-epi-docetaxel 생성량(area%) | |
0hr | 99.7469 | 0 | 99.7480 | 0 |
1hr | 95.7399 | 4.0163 | 99.2959 | 0.4494 |
5hr | 81.8743 | 17.2282 | 97.8546 | 1.8948 |
10hr | 69.3707 | 28.4728 | 96.8045 | 2.9451 |
24hr | 50.7338 | 41.5352 | 95.1952 | 4.5544 |
Claims (13)
- 도세탁셀 함유물 또는 도세탁셀을 극성 용매에 1 내지 30%(w/v) 농도로 용해시키고;상기 얻어진 용액을 5배 이상의 부피의 비극성 용매에 가하여 침전을 생성시키고;상기 생성된 침전을 여과하고 건조하여 무정형의 도세탁셀을 수득하는 단계를 포함하고,상기 극성 용매는 디클로로메탄 및 아세톤으로 이루어진 군 중에서 선택된 1종 이상의 것이고,상기 비극성 용매는 헥산 및 펜탄으로 이루어진 군 중에서 선택된 1종 이상의 것인,무정형 도세탁셀의 제조 방법.
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
- 삭제
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060000276A KR100995390B1 (ko) | 2006-01-02 | 2006-01-02 | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 |
EP06812378.5A EP1973894B1 (en) | 2006-01-02 | 2006-11-02 | Method for preparation of amorphous, anhydrous crystalline, or hydrated crystalline docetaxel |
ES06812378.5T ES2576635T3 (es) | 2006-01-02 | 2006-11-02 | Método para la preparación de docetaxel amorfo, cristalino anhidro o cristalino hidratado |
JP2008549408A JP5149810B2 (ja) | 2006-01-02 | 2006-11-02 | 無定形、無水結晶形または水和結晶形ドセタキセルの製造方法 |
US12/159,812 US8163940B2 (en) | 2006-01-02 | 2006-11-02 | Method for preparation of amorphous, anhydrous crystalline or hydrated crystalline docetaxel |
PCT/KR2006/004539 WO2007078050A2 (en) | 2006-01-02 | 2006-11-02 | Method for preparation of amorphous, anhydrous crystalline, or hydrated crystalline docetaxel |
CN2006800517030A CN101415697B (zh) | 2006-01-02 | 2006-11-02 | 制备非晶的多西紫杉醇的方法 |
BRPI0620850-9A BRPI0620850A2 (pt) | 2006-01-02 | 2006-11-02 | mÉtodos de preparaÇço de docetaxel amorfo e cristalino, anidro e hidratado |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020060000276A KR100995390B1 (ko) | 2006-01-02 | 2006-01-02 | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020090055965A Division KR100965867B1 (ko) | 2009-06-23 | 2009-06-23 | 수화결정형 도세탁셀의 제조방법 |
KR1020090055964A Division KR100965866B1 (ko) | 2009-06-23 | 2009-06-23 | 무수결정형 도세탁셀의 제조방법 |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20070072786A KR20070072786A (ko) | 2007-07-05 |
KR100995390B1 true KR100995390B1 (ko) | 2010-11-19 |
Family
ID=38228618
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020060000276A Active KR100995390B1 (ko) | 2006-01-02 | 2006-01-02 | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 |
Country Status (8)
Country | Link |
---|---|
US (1) | US8163940B2 (ko) |
EP (1) | EP1973894B1 (ko) |
JP (1) | JP5149810B2 (ko) |
KR (1) | KR100995390B1 (ko) |
CN (1) | CN101415697B (ko) |
BR (1) | BRPI0620850A2 (ko) |
ES (1) | ES2576635T3 (ko) |
WO (1) | WO2007078050A2 (ko) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7435249B2 (en) * | 1997-11-12 | 2008-10-14 | Covidien Ag | Electrosurgical instruments which reduces collateral damage to adjacent tissue |
WO2008051465A2 (en) * | 2006-10-20 | 2008-05-02 | Scinopharm Singapore Pte, Ltd. | Process for making crystalline anhydrous docetaxel |
WO2008102374A1 (en) * | 2007-02-20 | 2008-08-28 | Dabur Pharma Limited | Amorphous form of docetaxel |
KR100878455B1 (ko) * | 2007-04-10 | 2009-01-13 | 한미약품 주식회사 | 안정한 무수결정형 도세탁셀 및 이의 제조방법 |
WO2009006590A2 (en) * | 2007-07-04 | 2009-01-08 | Dr. Reddy's Laboratories Ltd. | Docetaxel process and polymorphs |
ES2389518T3 (es) * | 2008-01-18 | 2012-10-26 | Indena S.P.A. | Formas sólidas de ortataxel |
KR101053780B1 (ko) * | 2008-02-29 | 2011-08-02 | 동아제약주식회사 | 도세탁셀을 함유하는 단일액상의 안정한 약제학적 조성물 |
KR101068230B1 (ko) * | 2009-03-03 | 2011-09-28 | 정규능 | 도세탁셀의 제조방법, 그 중간체 및 이의 제조방법 |
JP2012522055A (ja) * | 2009-03-30 | 2012-09-20 | セルリアン・ファーマ・インコーポレイテッド | ポリマー‐薬剤抱合体、粒子、組成物、および関連する使用方法 |
WO2010114768A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-epothilone conjugates, particles, compositions, and related methods of use |
WO2010114770A1 (en) * | 2009-03-30 | 2010-10-07 | Cerulean Pharma Inc. | Polymer-agent conjugates, particles, compositions, and related methods of use |
US8686165B2 (en) * | 2009-11-04 | 2014-04-01 | Emcure Pharmaceuticals Limited | Process for preparation of taxane derivatives |
KR101149600B1 (ko) * | 2009-12-31 | 2012-05-29 | 주식회사 삼양제넥스바이오 | 고순도 무수결정형 도세탁셀 제조방법 |
BR112012028037A2 (pt) | 2010-05-03 | 2016-08-02 | Teikoku Pharma Usa Inc | formulação de pró-emulsão líquida de taxano não aquosa, métodos para administrar um taxano a um paciente e para fabricar uma formulação de pró-emulsão de taxano, composição de emulsão de taxano, e, kit |
ES2621800T3 (es) * | 2011-04-12 | 2017-07-05 | Teva Pharmaceuticals International Gmbh | Formas de estado sólido de cabazitaxel y procesos de preparación de las mismas |
WO2012160568A1 (en) * | 2011-05-23 | 2012-11-29 | Shilpa Medicare Limited | Process for preparing docetaxel trihydrate polymorph |
JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
US9629629B2 (en) | 2013-03-14 | 2017-04-25 | Ethicon Endo-Surgey, LLC | Control systems for surgical instruments |
CN103601704B (zh) * | 2013-11-22 | 2015-05-06 | 石家庄智恒医药科技有限公司 | 无定形卡巴他赛的制备 |
EP4403223A3 (en) * | 2014-06-06 | 2024-10-09 | AbbVie Inc. | Crystal forms |
CN111039984B (zh) * | 2018-10-15 | 2022-06-07 | 上海盟科药业股份有限公司 | 康泰唑胺酯的药物晶体及其制备方法和应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996001815A1 (fr) | 1994-07-08 | 1996-01-25 | Rhone-Poulenc Rorer S.A. | PROCEDE DE PREPARATION DU TRIHYDRATE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YLE |
WO2004099167A1 (fr) | 2003-05-08 | 2004-11-18 | Shanghai Desano Chemical Pharmaceutical Co., Ltd. | Procede de preparation de docetaxel trihydrate |
WO2005061474A1 (en) | 2003-12-12 | 2005-07-07 | Quiral Química Do Brasil | Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100290635B1 (ko) | 1998-12-23 | 2001-06-01 | 박종헌 | 무정형 팩리택셀의 제조방법 |
US6881852B2 (en) * | 2002-02-05 | 2005-04-19 | Dabur India Limited | Process of purification of paclitaxel and docetaxel |
US6838569B2 (en) | 2002-12-16 | 2005-01-04 | Dabur India Limited | Process for preparation of paclitaxel trihydrate and docetaxel trihydrate |
CN100420681C (zh) * | 2005-04-29 | 2008-09-24 | 上海奥锐特国际贸易有限公司 | 多烯紫杉醇三水物的制备方法 |
US20070142457A1 (en) | 2005-10-12 | 2007-06-21 | Alessandro Pontiroli | Crystalline forms of docetaxel and processes for their preparation |
-
2006
- 2006-01-02 KR KR1020060000276A patent/KR100995390B1/ko active Active
- 2006-11-02 US US12/159,812 patent/US8163940B2/en active Active
- 2006-11-02 JP JP2008549408A patent/JP5149810B2/ja active Active
- 2006-11-02 CN CN2006800517030A patent/CN101415697B/zh active Active
- 2006-11-02 WO PCT/KR2006/004539 patent/WO2007078050A2/en active Application Filing
- 2006-11-02 BR BRPI0620850-9A patent/BRPI0620850A2/pt not_active IP Right Cessation
- 2006-11-02 EP EP06812378.5A patent/EP1973894B1/en active Active
- 2006-11-02 ES ES06812378.5T patent/ES2576635T3/es active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996001815A1 (fr) | 1994-07-08 | 1996-01-25 | Rhone-Poulenc Rorer S.A. | PROCEDE DE PREPARATION DU TRIHYDRATE DU (2R,3S)-3-TERT-BUTOXYCARBONYLAMINO-2-HYDROXY-3-PHENYLPROPIONATE DE 4-ACETOXY-2α-BENZOYLOXY-5β,20-EPOXY-1,7β,10β-TRIHYDROXY-9-OXO-TAX-11-EN-13α-YLE |
WO2004099167A1 (fr) | 2003-05-08 | 2004-11-18 | Shanghai Desano Chemical Pharmaceutical Co., Ltd. | Procede de preparation de docetaxel trihydrate |
WO2005061474A1 (en) | 2003-12-12 | 2005-07-07 | Quiral Química Do Brasil | Process for the preparation of anhydrous and hydrated active pharmaceutical ingredients (apis); stable pharmaceutical compositions prepared from the same and uses of said compositions |
Also Published As
Publication number | Publication date |
---|---|
EP1973894A2 (en) | 2008-10-01 |
EP1973894A4 (en) | 2010-11-17 |
BRPI0620850A2 (pt) | 2013-01-29 |
CN101415697A (zh) | 2009-04-22 |
EP1973894B1 (en) | 2016-04-06 |
US8163940B2 (en) | 2012-04-24 |
US20090018353A1 (en) | 2009-01-15 |
JP2009522351A (ja) | 2009-06-11 |
ES2576635T3 (es) | 2016-07-08 |
KR20070072786A (ko) | 2007-07-05 |
WO2007078050A2 (en) | 2007-07-12 |
WO2007078050A3 (en) | 2008-01-03 |
CN101415697B (zh) | 2012-10-17 |
JP5149810B2 (ja) | 2013-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100995390B1 (ko) | 무정형, 무수결정형 또는 수화 결정형 도세탁셀의 제조방법 | |
EP3216790B1 (en) | Crystalline form of jak kinase inhibitor bisulfate and a preparation method thereof | |
JP6321735B2 (ja) | エルタペネムナトリウムの結晶形およびその調製方法 | |
RU2006121341A (ru) | Кристаллические формы дигидрохлорида (6r)-l-эритро-тетрагидробиоптерина | |
JPH09506601A (ja) | 結晶性n−アセチルノイラミン酸誘導体およびその製造法 | |
WO2008102374A1 (en) | Amorphous form of docetaxel | |
KR100965867B1 (ko) | 수화결정형 도세탁셀의 제조방법 | |
CN103874692A (zh) | 卡巴他赛的无定形形式和用于其制备的方法 | |
KR100965866B1 (ko) | 무수결정형 도세탁셀의 제조방법 | |
KR101596554B1 (ko) | 펩타이드계 물질의 결정체 및 그의 제조방법과 용도 | |
EP2316840A1 (en) | Ibandronate Sodium Polymorphs | |
CN106866533B (zh) | 吡唑醚菌酯晶型及制备方法 | |
KR100965869B1 (ko) | 수화결정형 파클리탁셀의 제조방법 | |
ES2836099T3 (es) | Cristal de un complejo de L-prolina/inhibidor del cotransportador de sodio-glucosa tipo 2 | |
CN105246907B (zh) | 阿贝卡星衍生物及其制造和利用 | |
CN102911158B (zh) | 埃索美拉唑镁的晶型 | |
KR100965868B1 (ko) | 무수결정형 파클리탁셀의 제조방법 | |
KR20060004330A (ko) | 무정형, 무수결정형 및 수화결정형 파클리탁셀의 제조방법 | |
WO2011085130A1 (en) | Solid state forms of fosamprenavir calcium salt and process for preparation thereof | |
WO2025132408A2 (en) | Solvates of trametinib | |
CN105461739A (zh) | 结晶头孢嗪脒钠及其制备方法和用途 | |
JP5608666B2 (ja) | 2種のピノセンブリン、その製造方法、および、医薬組成物の製造におけるその使用 | |
EP3502124A9 (en) | Crystal of sulfate of polymyxin b1, b2, or mixture thereof, and manufacturing method of same | |
HK1014187B (en) | Crystalline n-acetyl neuraminic acid derivatives and processes for their preparation | |
KR20090008512A (ko) | 세포테탄 이나트륨염의 신규 제조방법 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20060102 |
|
PG1501 | Laying open of application | ||
A201 | Request for examination | ||
PA0201 | Request for examination |
Patent event code: PA02012R01D Patent event date: 20071023 Comment text: Request for Examination of Application Patent event code: PA02011R01I Patent event date: 20060102 Comment text: Patent Application |
|
E902 | Notification of reason for refusal | ||
PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20090225 Patent event code: PE09021S01D |
|
A107 | Divisional application of patent | ||
PA0107 | Divisional application |
Comment text: Divisional Application of Patent Patent event date: 20090623 Patent event code: PA01071R01D |
|
E601 | Decision to refuse application | ||
PE0601 | Decision on rejection of patent |
Patent event date: 20090805 Comment text: Decision to Refuse Application Patent event code: PE06012S01D Patent event date: 20090225 Comment text: Notification of reason for refusal Patent event code: PE06011S01I |
|
J201 | Request for trial against refusal decision | ||
PJ0201 | Trial against decision of rejection |
Patent event date: 20090904 Comment text: Request for Trial against Decision on Refusal Patent event code: PJ02012R01D Patent event date: 20090805 Comment text: Decision to Refuse Application Patent event code: PJ02011S01I Appeal kind category: Appeal against decision to decline refusal Decision date: 20101030 Appeal identifier: 2009101008272 Request date: 20090904 |
|
J301 | Trial decision |
Free format text: TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20090904 Effective date: 20101030 |
|
PJ1301 | Trial decision |
Patent event code: PJ13011S01D Patent event date: 20101101 Comment text: Trial Decision on Objection to Decision on Refusal Appeal kind category: Appeal against decision to decline refusal Request date: 20090904 Decision date: 20101030 Appeal identifier: 2009101008272 |
|
GRNT | Written decision to grant | ||
PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20101112 Patent event code: PR07011E01D |
|
PR1002 | Payment of registration fee |
Payment date: 20101112 End annual number: 3 Start annual number: 1 |
|
PG1601 | Publication of registration | ||
FPAY | Annual fee payment |
Payment date: 20130830 Year of fee payment: 4 |
|
PR1001 | Payment of annual fee |
Payment date: 20130830 Start annual number: 4 End annual number: 4 |
|
FPAY | Annual fee payment |
Payment date: 20150903 Year of fee payment: 6 |
|
PR1001 | Payment of annual fee |
Payment date: 20150903 Start annual number: 6 End annual number: 6 |
|
FPAY | Annual fee payment |
Payment date: 20160902 Year of fee payment: 7 |
|
PR1001 | Payment of annual fee |
Payment date: 20160902 Start annual number: 7 End annual number: 7 |
|
FPAY | Annual fee payment |
Payment date: 20170905 Year of fee payment: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20170905 Start annual number: 8 End annual number: 8 |
|
PR1001 | Payment of annual fee |
Payment date: 20200903 Start annual number: 11 End annual number: 11 |
|
PR1001 | Payment of annual fee |
Payment date: 20210906 Start annual number: 12 End annual number: 12 |
|
PR1001 | Payment of annual fee |
Payment date: 20220905 Start annual number: 13 End annual number: 13 |
|
PR1001 | Payment of annual fee |
Payment date: 20230905 Start annual number: 14 End annual number: 14 |